The Efficacy of Platelets Rich Plasma for Ovarian Rejuvenation

The Efficacy of Platelets Rich Plasma (PRP) for Ovarian Rejuvenation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03946813

Enrollment

Registered

2019-05-13

Start date

2018-08-20

Completion date

2019-05-31

Last updated

2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Keywords

Ovarian Rejuvenation , Infertility

Brief summary

In recent years, an increased approach has appeared in the use of autologous blood products to assist tissue and organ healing. Application of platelet rich plasma (PRP) has emerged as a potential solution for infertile women with poor ovarian reserve in reproductive specialty.

Detailed description

Quantitative and qualitative functional improvement of ovarian function has been reported in several studies after using autologous PRP in a reproductive field. Ovarian rejuvenation, stimulating the ovaries to produce new eggs after injecting PRP, can offer hope for renewed fertility to women with poor reserve volume, advanced maternal age, or either naturally occurring or premature menopause. But, these encouraging results should be supported by several new studies. This study aimed to estimate the efficacy of trans-vaginal ovarian injection with PRP in rejuvenates ovaries in woman with poor ovarian reserve, and to assess any association of some women variables (age, menstrual status, parity, BMI) as predicting factors in success of ovarian injection with PRP.

Interventions

OTHERAutologous PRP preparation

For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 49 Years

Healthy volunteers

Inclusion criteria

1. Menopause or peri-menopause under the age of 50. 2. Premature ovarian insufficiency which is ovarian failure before the age of 40. 3. Woman with primary ovarian failure of any cause.

Exclusion criteria

1. A previous injection with any medication, plasma, or PRP 2. Invisible or difficult access ovaries. 3. Medical disease or unfit for anesthesia patient.

Design outcomes

Primary

Measure	Time frame	Description
Follicle-stimulating hormone (FSH) concentration	4 weeks	Before after intervention measurement
Anti-Müllerian hormone (AMH) concentration	4 weeks	Before after intervention measurement
Antral follicles numbers	4 weeks	Before after intervention measurement

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026